Quarterly report pursuant to Section 13 or 15(d)

Warrants - Schedule of Warrants Outstanding (Details)

v3.19.3
Warrants - Schedule of Warrants Outstanding (Details) - $ / shares
 9 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Dec. 31, 2017
Warrant Outstanding Exercise Price $ 1.08 $ 1.74 $ 3.10
Warrants Outstanding 26,538,593 7,371,925 2,177,425
Range One [Member]      
Warrant Outstanding Exercise Price $ 3.10    
Warrants Outstanding 48,387    
Expiration Date Sep. 19, 2022    
Range Two [Member]      
Warrant Outstanding Exercise Price $ 2.00    
Warrants Outstanding 900,000    
Expiration Date Apr. 10, 2023    
Range Three [Member]      
Warrant Outstanding Exercise Price $ 3.10    
Warrants Outstanding 462,106    
Expiration Date May 10, 2024    
Range Four [Member]      
Warrant Outstanding Exercise Price $ 3.10    
Warrants Outstanding 602,414    
Expiration Date Jul. 25, 2024    
Range Five [Member]      
Warrant Outstanding Exercise Price $ 3.10    
Warrants Outstanding 1,064,518    
Expiration Date Nov. 08, 2024    
Range Six [Member]      
Warrant Outstanding Exercise Price $ 1.00    
Warrants Outstanding 4,294,500    
Expiration Date Jul. 17, 2025    
Range Seven [Member]      
Warrant Outstanding Exercise Price $ 0.75    
Warrants Outstanding 9,583,334    
Expiration Date [1] Sep. 25, 2020    
Range Eight [Member]      
Warrant Outstanding Exercise Price $ 0.90    
Warrants Outstanding 9,583,334    
Expiration Date Mar. 25, 2024    
[1] Subject to termination prior to the indicated date following the Company's release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013 plus twenty-one (21) trading days.